Close Menu

NEW YORK – Adaptive Biotechnologies said Monday after the close of the market that its second quarter revenues decreased 5 percent year over year, primarily due to a COVID-19 pandemic-related drop in its sequencing business.

For the three months ended June 30, 2020, the Seattle-based immune sequencing firm tallied revenues of $21.0 million compared to $22.1 million a year ago, ahead of analysts' average estimate of $18.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.